About beam therapeutics inc. - BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
BEAM At a Glance
Beam Therapeutics, Inc.
238 Main Street
Cambridge, Massachusetts 02142-1016
| Phone | 1-857-327-8775 | Revenue | 139.74M | |
| Industry | Biotechnology | Net Income | -79,992,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 120.005% | |
| Fiscal Year-end | 12 / 2026 | Employees | 511 | |
| View SEC Filings |
BEAM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 19.619 |
| Price to Book Ratio | 2.278 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.567 |
| Enterprise Value to Sales | 11.812 |
| Total Debt to Enterprise Value | 0.093 |
BEAM Efficiency
| Revenue/Employee | 273,469.667 |
| Income Per Employee | -156,540.117 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.108 |
BEAM Liquidity
| Current Ratio | 13.088 |
| Quick Ratio | 13.088 |
| Cash Ratio | 12.846 |
BEAM Profitability
| Gross Margin | 84.046 |
| Operating Margin | -274.57 |
| Pretax Margin | -57.242 |
| Net Margin | -57.242 |
| Return on Assets | -6.189 |
| Return on Equity | -8.113 |
| Return on Total Capital | -5.745 |
| Return on Invested Capital | -7.08 |
BEAM Capital Structure
| Total Debt to Total Equity | 12.446 |
| Total Debt to Total Capital | 11.068 |
| Total Debt to Total Assets | 10.405 |
| Long-Term Debt to Equity | 11.286 |
| Long-Term Debt to Total Capital | 10.037 |